受强制性开放获取政策约束的文章 - Joshua Richter了解详情
可在其他位置公开访问的文章：22 篇
Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma
J Richter, N Neparidze, L Zhang, S Nair, T Monesmith, R Sundaram, ...
Blood, The Journal of the American Society of Hematology 121 (3), 423-430, 2013
强制性开放获取政策： US National Institutes of Health
Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma
DT Vogl, D Dingli, RF Cornell, CA Huff, S Jagannath, D Bhutani, J Zonder, ...
Journal of clinical oncology 36 (9), 859-866, 2018
强制性开放获取政策： US National Institutes of Health
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
B Wang, O Van Oekelen, TH Mouhieddine, DM Del Valle, J Richter, ...
Journal of hematology & oncology 13, 1-12, 2020
强制性开放获取政策： US National Institutes of Health
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
M Gavriatopoulou, A Chari, C Chen, N Bahlis, DT Vogl, A Jakubowiak, ...
Leukemia 34 (9), 2430-2440, 2020
强制性开放获取政策： US National Institutes of Health
COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
M Hultcrantz, J Richter, CA Rosenbaum, D Patel, EL Smith, N Korde, ...
Blood cancer discovery 1 (3), 234-243, 2020
强制性开放获取政策： US National Institutes of Health, Swedish Research Council
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
O Van Oekelen, K Nath, TH Mouhieddine, T Farzana, A Aleman, ...
Blood 141 (7), 756-765, 2023
强制性开放获取政策： US National Institutes of Health
Venetoclax induces deep hematologic remissions in t (11; 14) relapsed/refractory AL amyloidosis
VJ Premkumar, S Lentzsch, S Pan, D Bhutani, J Richter, S Jagannath, ...
Blood cancer journal 11 (1), 10, 2021
强制性开放获取政策： US National Institutes of Health
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
S Bhalla, DT Melnekoff, A Aleman, V Leshchenko, P Restrepo, J Keats, ...
Science advances 7 (47), eabg9551, 2021
强制性开放获取政策： US National Institutes of Health
Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges
MV Dhodapkar, J Richter
Clinical immunology 140 (2), 160-166, 2011
强制性开放获取政策： US National Institutes of Health
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
J Mikhael, J Richter, R Vij, C Cole, J Zonder, JL Kaufman, W Bensinger, ...
Leukemia 34 (12), 3298-3309, 2020
强制性开放获取政策： US National Institutes of Health
IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies
G Lancman, K Parsa, K Kotlarz, L Avery, A Lurie, A Lieberman-Cribbin, ...
Blood Cancer Discovery 4 (6), 440-451, 2023
强制性开放获取政策： Polish National Agency for Academic Exchange
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
X Leleu, T Martin, K Weisel, F Schjesvold, S Iida, F Malavasi, S Manier, ...
Annals of Hematology 101 (10), 2123-2137, 2022
强制性开放获取政策： Cancer Research UK
Myeloma CAR-T CRS management with IL-1R antagonist anakinra
SS Jatiani, A Aleman, D Madduri, A Chari, HJ Cho, S Richard, J Richter, ...
Clinical Lymphoma Myeloma and Leukemia 20 (9), 632-636. e1, 2020
强制性开放获取政策： US National Institutes of Health
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
TH Mouhieddine, O Van Oekelen, DT Melnekoff, J Li, Y Ghodke-Puranik, ...
Blood Advances 7 (6), 1056-1064, 2023
强制性开放获取政策： US National Institutes of Health
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
A Aleman, O Van Oekelen, B Upadhyaya, K Beach, AK Zajdman, ...
Cancer cell 40 (5), 441-443, 2022
强制性开放获取政策： US National Institutes of Health
A three-gene signature predicts response to selinexor in multiple myeloma
P Restrepo, S Bhalla, Y Ghodke-Puranik, A Aleman, V Leshchenko, ...
JCO Precision Oncology 6, e2200147, 2022
强制性开放获取政策： US National Institutes of Health
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
G Tremblay, P Daniele, J Breeze, L Li, J Shah, S Shacham, M Kauffman, ...
BMC cancer 21, 1-10, 2021
强制性开放获取政策： US National Institutes of Health
Graft-versus-host disease in multiple myeloma patients treated with daratumumab after allogeneic transplantation
L Nikolaenko, S Chhabra, N Biran, A Chowdhury, PN Hari, A Krishnan, ...
Clinical Lymphoma Myeloma and Leukemia 20 (6), 407-414, 2020
强制性开放获取政策： US National Institutes of Health
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups
UA Shah, E Moshier, A Derkach, Y Huang, S Mailankody, CR Tan, ...
Blood Advances 8 (1), 236-247, 2024
强制性开放获取政策： US National Institutes of Health
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma
A Aleman, M Van Kesteren, AK Zajdman, K Srivastava, C Cognigni, ...
EBioMedicine 98, 2023
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定